Hyperion DeFi Inc. (HYPD)
HYPD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1682639/000110465926036286/0001104659-26-036286-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HYPD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001682639 |
| SEC industry code | Finance Services |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $813K |
| Net income | -$45.3M |
| Operating income | -$46.7M |
| Net margin | -5570.6% |
| Operating margin | -5743.5% |
| Revenue growth | +1318.8% |
| Cash | $6.4M |
| Total assets | $51.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 47.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Under Accounting Standards Codification ( ASC ) Subtopic 205-40, Presentation of Financial Statements Going Concern, the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet future financial obligations as they become due within one year after the date that these financial statements are issued." | 10-Q 2026-11-13 |
| Cash and burn | $6.6M cash; operating cash flow -$3.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 15,488,133 (2026-11-09); 8,097,659 a year earlier; 44,122,225 three years earlier. 3y figure adjusted for split (1-for-80 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 1; latest 1-for-80 on 2025-02-03 | Source 2025-02-03 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-05-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $641K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $810K | $39.6M | -$1.7M | $6.6M | $183K | $1.9M | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | $358K | $31.0M | -$2.9M | $9.6M | $8.4M | $1.4M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $244K | $8.8M | -$4.2M | $7.4M | $8.5M | $1.0M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $496K | -$39.8M | -$4.1M | $6.3M | $16.1M | $813K | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $303K | $6.6M | -$2.8M | $8.2M | $8.3M | $345K | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | $0 | -$8.7M | -$3.4M | $7.5M | $8.2M | $44K | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $15K | -$3.5M | -$4.4M | $3.9M | $20.1M | $67K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $28K | -$20.0M | -$6.1M | $2.1M | $15.5M | $57K | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-06 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-13 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-05-05 |
Source: SEC EDGAR submissions feed, 619 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.6% |
| 1 month | -23.2% |
| 3 months | -8.8% |
| Year to date | -27.5% |
| 1 year | -48.1% |
| From 52-week high | -48.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
| SER | Serina Therapeutics Inc. | $1.42 | +2.16% | $37.7M |
| GRCE | Grace Therapeutics Inc. | $1.75 | -3.31% | $36.8M |
| ALDX | Aldeyra Therapeutics Inc. | $0.6696 | +4.01% | $40.4M |
| CNTB | Connect Biopharma Holdings Limited | $0.6430 | -5.05% | $40.5M |
| DWTX | Dogwood Therapeutics Inc. | $1.06 | -8.62% | $40.5M |
| ATHE | Alterity Therapeutics Limited | $1.96 | 0.00% | $35.7M |
| VERU | Veru Inc. | $2.08 | -0.48% | $35.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier